靶向和免疫治疗原发性肝癌:肝移植术前降期治疗应用进展*

doi:10.3969/j.issn.1672-5069.2024.06.003

实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (6): 808-811.doi: 10.3969/j.issn.1672-5069.2024.06.003

靶向和免疫治疗原发性肝癌:肝移植术前降期治疗应用进展^*

朱泽斌, 张树庚, 刘连新

230036 合肥市中国科学技术大学附属第一医院/安徽省立医院肝移植科(朱泽斌,张树庚);肝胆外科(刘连新)

收稿日期:2023-10-26 出版日期:2024-11-10 发布日期:2024-11-07
通讯作者: 刘连新,E-mail: liulx@ustc.edu.cn
作者简介:朱泽斌,男,33岁,博士研究生,主治医师。E-mail:18826431159@163.com
基金资助:
^*中央高校基本科研业务费专项资金资助(编号:WK9110000170)

Targeted therapy and immunotherapy in downstaging of patients with hepatocellular carcinoma before liver transplantation

Zhu Zebin, Zhang Shugeng, Liu Lianxin

Liver Transplantation Center, First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230036, Anhui Province, China

Received:2023-10-26 Online:2024-11-10 Published:2024-11-07

摘要/Abstract

关键词: 肝细胞癌, 肝移植, 靶向治疗, 免疫治疗, 降期治疗

Key words: Hepatocellular carcinoma, Liver transplantation, Targeted therapy, Immunotherapy, Downstaging therapy

朱泽斌, 张树庚, 刘连新. 靶向和免疫治疗原发性肝癌:肝移植术前降期治疗应用进展^*[J]. 实用肝脏病杂志, 2024, 27(6): 808-811.

Zhu Zebin, Zhang Shugeng, Liu Lianxin. Targeted therapy and immunotherapy in downstaging of patients with hepatocellular carcinoma before liver transplantation[J]. Journal of Practical Hepatology, 2024, 27(6): 808-811.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021,71(3):209-249.
[2] Imamura J, Tateishi R, Shiina S, et al. Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol, 2008, 103(12):3057-3062.
[3] 郑树森, 董家鸿, 窦科峰,等. 中国肝癌肝移植临床实践指南(2021年版). 中华移植杂志(电子版), 2021, 15(6):321-328.
[4] Tran NH, Muñoz S, Thompson S, et al. Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF/TKI and immunotherapy. Hepatology, 2022, 76(4):1203-1218.
[5] Golse N, Radenne S, Rode A, et al. Liver transplantation after neoadjuvant sorafenib therapy: Preliminary experience and literature review. Exp Clin Transplant, 2018, 16(2):227-236.
[6] Frenette CT, Boktour M, Burroughs SG, et al. Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation. Transpl Int, 2013,26(7):734-739.
[7] 鲁旭, 李华, 易述红,等. 介入联合仑伐替尼桥接治疗超米兰标准肝癌肝移植2例报道. 岭南现代临床外科, 2021, 21(5):507-511.
[8] Eilard MS, Andersson M, Naredi P, et al. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. BMC Cancer, 2019, 19(1):568.
[9] Schwacha-Eipper B, Minciuna I, Banz V, et al. Immunotherapy as a downstaging therapy for liver transplantation. Hepatology, 2020, 72(4):1488-1490.
[10] Schnickel GT, Fabbri K, Hosseini M, et al. Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab. Am J Transplant, 2022,22(6):1699-1704.
[11] Tabrizian P, Florman SS, Schwartz ME. PD-1 inhibitor as bridge therapy to liver transplantation? Am J Transplant, 2021, 21(5):1979-1980.
[12] Wang T, Chen Z, Liu Y, et al. Neoadjuvant programmed cell death 1 inhibitor before liver transplantation for HCC is not associated with increased graft loss. Liver Transpl, 2023, 29(6):598-606.
[13] Wang Y, Jiang M, Zhu J, et al. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma. Biomed Pharmacother, 2020,132:110797.
[14] Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med, 2020, 382(20):1894-1905.
[15] Qiao ZY, Zhang ZJ, Lv ZC, et al. Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: A cohort study and literature review. Front Immunol, 2021, 12:653437.
[16] Schmiderer A, Zoller H, Niederreiter M, et al. Liver transplantation after successful downstaging of a locally advanced hepatocellular carcinoma with systemic therapy. Dig Dis, 2023, 41(4):641-644.
[17] Giudicelli H, Roux C, Monsel A, et al. Successful advanced hepatocellular carcinoma downstaging with atezolizumab-Bevacizumab and radioembolization before liver transplantation. Clin Res Hepatol Gastroenterol, 2023, 47(7):102167.
[18] Chiang CL, Chiu KWH, Chan KSK, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. Lancet Gastroenterol Hepatol, 2023, 8(2):169-178.
[19] Brown ZJ, Hewitt DB, Pawlik TM. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. Expert Opin Investig Drugs, 2022, 31(4):379-391.
[20] Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol, 2017, 66(3):545-551.
[21] Harding JJ, Nandakumar S, Armenia J, et al. Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res, 2019, 25(7):2116-2126.
[22] Adebayo Michael AO, Ko S, Tao J, et al. Inhibiting glutamine-dependent mTORC1 activation ameliorates liver cancers driven by β-catenin mutations. Cell Metab, 2019,29(5):231-236.
[23] Mizukoshi E, Kaneko S. Immune cell therapy for hepatocellular carcinoma. J Hematol Oncol,2019,12(1):52.

靶向和免疫治疗原发性肝癌:肝移植术前降期治疗应用进展^*

Targeted therapy and immunotherapy in downstaging of patients with hepatocellular carcinoma before liver transplantation

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张少博, 张树庚, 刘连新. 免疫治疗肝细胞癌肝移植患者现状和前景展望^*[J]. 实用肝脏病杂志, 2024, 27(6): 801-803.
[2]	郑浩, 张树庚, 王嘉倍, 郭亚飞. 肝移植术治疗肝细胞癌患者肿瘤复发再治疗策略^*[J]. 实用肝脏病杂志, 2024, 27(6): 804-807.
[3]	曾旺, 蔡晓曼, 葛尚. 肝内胆管细胞癌与肝细胞癌病灶MRI增强扫描表现差异分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 907-910.
[4]	丹巴玉珍, 程盼. 增强MRI检查诊断HCC价值研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 911-914.
[5]	杨佳欣, 杨紫郡, 陈卫. 双源CT双能量TNC技术图像质量与诊断肝细胞癌效能分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 915-918.
[6]	王玲玲, 姚敏, 姚登福. 肝细胞癌进展过程中KLFs异常表达及其检测的临床价值研究进展^*[J]. 实用肝脏病杂志, 2024, 27(6): 953-956.
[7]	张伟萍, 戈宏焱. 细胞焦亡及其在肝细胞癌发病过程中的作用研究进展[J]. 实用肝脏病杂志, 2024, 27(5): 797-800.
[8]	廖敏君, 饶慧瑛. 脂肪性肝病相关肝细胞癌筛查和监测策略[J]. 实用肝脏病杂志, 2024, 27(4): 484-487.
[9]	夏礼鹏, 褚玉玄, 赵如盛. 增强MRI联合IVIM-DWI诊断小肝细胞癌价值研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 587-590.
[10]	徐思洁, 秦浩, 张振华. 应用加权基因共表达网络分析识别肝细胞癌发生和进展过程中关键通路和基因作用研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 599-602.
[11]	田春燕, 罗莉, 曹雪玲, 熊萍. 采用超声造影灌注及回声变化规律鉴别诊断肝血管瘤与肝细胞癌价值研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 603-606.
[12]	隋虎, 毛佳, 陈露, 王超逸, 兰邦涛. CT定量参数鉴别诊断肝局灶性结节增生与肝细胞癌的价值研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 611-614.
[13]	倪裕丰, 倪国英, 杨志勇. 肝细胞癌组织BCLAF1和TCF3 RNA水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 418-421.
[14]	梅文娟, 李新, 张昊月. 超声造影时间-强度曲线相关参数鉴别诊断肝细胞癌与转移性肝癌价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 430-433.
[15]	罗珂, 丁莉, 刘美. 肝细胞癌患者癌组织TTF-1、p53、p63表达变化及其对术后生存的影响^*[J]. 实用肝脏病杂志, 2024, 27(3): 434-437.